Cargando…

Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women With Osteoporosis Switching From 60mg to 30mg 6 Monthly: A Real World, Prospective Observational Study

Introduction: Denosumab, a fully human monoclonal antibody to RANK-ligand, has been shown to increase bone mineral density (BMD) and reduce the risk of fracture in postmenopausal women with osteoporosis. Cessation of denosumab is associated with rises in bone remodelling, reductions in BMD and an in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Aliya, Alrob, Hajar Abu, Said, Hosay, Iqbal, Salman, Hweija, Ismail, Hussain, Sharjil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Bone and Mineral Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090192/ http://dx.doi.org/10.1210/jendso/bvab048.489

Ejemplares similares

SUN-377 Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Real World, Prospective Observational Study
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

OR01-5 Transition From Low Dose Denosumab 30mg to IV Zoledronic Acid: Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Prospective Observational Study
por: Ibrahim, Quazi, et al.
Publicado: (2022)

Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study
por: Khan, Aliya A., et al.
Publicado: (2023)

ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis
por: Hone, Namki, et al.
Publicado: (2022)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

SUN-391 Denosumab Treatment of Patients with Osteoporosis and Idiopathic Hypercalciuria
por: Chu, Winston S, et al.
Publicado: (2020)

FRI685 Denosumab Withdrawal Is Associated With Hypercalcemia In Adults With Osteoporosis And Bone Metastases
por: Patil, Madhuri D, et al.
Publicado: (2023)

SUN-512 Denosumab Improves Trabecular but Not Cortical Bone Osteoporosis in a Patient with Refractory Primary Hyperparathyroidism
por: Alhassan, Sharifa, et al.
Publicado: (2019)

OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
por: Lane, Nancy, et al.
Publicado: (2019)

Calcium of 19mg/dL and Yet Asymptomatic
por: Naqvi, Syeda, et al.
Publicado: (2021)

SUN-513 Parathyromatosis: A Case of Stubborn Hypercalcemia Treated with Denosumab
por: Ventura, Kenilia, et al.
Publicado: (2019)

MON-LB71 Adult Hypophosphatasia and Postmenopausal Osteoporosis: A Challenging Case
por: Abramof-Ness, Rosane, et al.
Publicado: (2020)

MON-LB091 An Overview of the Etiology, Clinical Manifestations, Management Strategies, and Complications of Hypoparathyroidism from the Canadian National Hypoparathyroidism Registry
por: Alalawi, Yousef, et al.
Publicado: (2019)

SAT-499 Denosumab for Treatment of Hypercalcemia in Myelofibrosis
por: Wong, Beatrice, et al.
Publicado: (2019)

MON-356 Atypical Femur Fracture with Denosumab
por: Mirza, Faryal S, et al.
Publicado: (2020)

ODP085 Denosumab Induced Severe Hypophosphatemia
por: Del Mar Morales Hernandez, Maria, et al.
Publicado: (2022)

SUN-396 Denosumab Preserves Bone Mineral Density at the Knee in Persons with Subacute Spinal Cord Injury
por: Bauman, William Alan, et al.
Publicado: (2020)

SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
por: Pyone, Zar Chi, et al.
Publicado: (2020)

SUN-389 Trends in Osteoporosis Treatment Uptake and Persistence Among Postmenopausal Women in the U.S., 2010–2015
por: Kim, Min, et al.
Publicado: (2020)

SAT-509 Denosumab Use in Tertiary Hiperparathyroidism with Fracture
por: Coy, Andres, et al.
Publicado: (2019)

Denosumab Induced Severe Prolonged Hypocalcemia in Metastatic Prostate Cancer
por: Mehmood, Hassan, et al.
Publicado: (2021)

Rebound Hypercalcemia After Denosumab Therapy in a Child With Cherubism
por: Litao, Melissa Kaori S, et al.
Publicado: (2021)

SUN-LB65 Circulating Micrornas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis
por: Yavropoulou, Maria, et al.
Publicado: (2020)

SAT-519 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture Representative of Covered Commercial Insurance Enrollees
por: Saag, Kenneth, et al.
Publicado: (2019)

MON-517 Treatment of Gorham-Stout Disease with Combination Sirolimus and Denosumab
por: Hartley, Iris, et al.
Publicado: (2019)

Denosumab Induced Severe Hypocalcemia in a Patient With Metastatic Prostate Cancer
por: Naher, Kamrun, et al.
Publicado: (2021)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

SUN-514 Severe Hypophosphatemia and Worsening Secondary Hyperparathyroidism Following Treatment with Denosumab
por: Adepoju, Yewande, et al.
Publicado: (2019)

MON-335 Bisphosphonate and Denosumab Refractory Hypercalcemia of Malignancy: What Else Is at Play?
por: Patel, Reshma, et al.
Publicado: (2020)

Prolonged Hypocalcemia After a Single Dose of Denosumab in Chronic Kidney Disease
por: Puar, Akshan, et al.
Publicado: (2021)

PSAT197 Treatment of Paget's Disease of the Skull With Denosumab: A Case Report
por: Torfah, Maisoon, et al.
Publicado: (2022)

THU448 Multiple Non-traumatic Vertebral Fractures After Discontinuation Of Denosumab
por: Riahi, Shayan, et al.
Publicado: (2023)

MON-378 Efficacy and Safety of Romosozumab vs Alendronate Is Similar Across Different Levels of Renal Function Among Postmenopausal Women with Osteoporosis
por: Miller, Paul, et al.
Publicado: (2020)

THU438 A Case Of Pregnancy Associated Osteoporosis
por: Maradana, Sandhya, et al.
Publicado: (2023)

THU426 Randomized Controlled Trial Comparing The Efficacy Of Teriparatide, Zoledronate And Denosumab In Postmenopausal Women With Type 2 Diabetes Mellitus At High Risk Of Fragility Fractures: 6-month Interim Analysis Of HR-pQCT Parameters
por: Pal, Rimesh, et al.
Publicado: (2023)

OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
por: Feldman, Robert, et al.
Publicado: (2020)

Rebound-Associated Vertebral Fractures Two Months After a Missed Dose of Denosumab
por: Caseja, Ahl Jeffrey, et al.
Publicado: (2021)

SAT258 Successful Treatment Of Adult T-cell Leukemia-lymphoma Induced Hypercalcemia With Denosumab
por: Yuksel, Simge, et al.
Publicado: (2023)

FRI684 So Strong Yet So Fragile: Bilateral Periprosthetic Fractures On Denosumab
por: Syeda, Asma, et al.
Publicado: (2023)

THU445 Complicated Course And Management After Denosumab Discontinuation: A Case Report
por: Arora, Ipsa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eqa73fnfc1mh0tdo5l4ct3mjrl